Mild to moderate Alzheimer dementia with insufficient neuropathological changes

Alberto Serrano-Pozo, Jing Qian, Sarah E. Monsell, Deborah Blacker, Teresa Gómez-Isla, Rebecca A. Betensky, John H. Growdon, Keith A. Johnson, Matthew P. Frosch, Reisa A. Sperling, Bradley T. Hyman

Research output: Contribution to journalArticlepeer-review


Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these "Aβ-negative" subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalAnnals of Neurology
Issue number4
StatePublished - Apr 2014

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Mild to moderate Alzheimer dementia with insufficient neuropathological changes'. Together they form a unique fingerprint.

Cite this